Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-ACVBP vs ACVBP in Low-risk Localized Diffuse Large B-cell Lymphoma
NCT00140660Phase 3Terminated
- Sponsor
- Lymphoma Study Association
- Start
- Dec 2003
- Primary completion
- Jul 2008
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Lymphoma Study Association. Started Dec 2003; status: terminated.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00140660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00140660.